KZIA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 16:59):

Stats
Šios dienos apimtis	26 949.00
Vidutinė apimtis	467 487
Rinkos kapitalizacija	6.37M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.730
ATR14	$0.00700 (2.60%)

Insider Trading

Date	Person	Action	Amount	type
2013-11-04	Austin Josiah T	Sell	25 400	Sponsored ADRs, each convertible into 25 ordinary shares
2013-11-05	Austin Josiah T	Sell	23 922	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-25	Austin Josiah T	Sell	62 591	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-28	Austin Josiah T	Sell	37 409	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-29	Austin Josiah T	Sell	1 100	Sponsored ADRs, each convertible into 25 ordinary shares

INSIDER POWER
0.00
Last 100 transactions
Buy: 5 568 614 \| Sell: 243 947

Tūris Koreliacija

Ilgas: -0.52 (weak negative)

Trumpas: -0.15 (neutral)

Signal:(49.329) Neutral

Kazia Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Kazia Therapeutics Koreliacija - Valiuta/Žaliavos

-0.39
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.41
( neutral )

Kazia Therapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$555.00
Bruto pelnas:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2023
Pajamos:	$555.00
Bruto pelnas:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2022
Pajamos:	$25.00
Bruto pelnas:	$25.00 (100.00 %)
EPS:	$-1.860

FY	2021
Pajamos:	$15.18M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.716

Financial Reports:

No articles found.

Kazia Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.